Status:
TERMINATED
Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
Lead Sponsor:
Neurotech Pharmaceuticals
Conditions:
Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
PHASE1
PHASE2
Brief Summary
Prospective, multi-center 2-stage study. Stage 1 (Phase I) is open-label with all patients treated with the NT-503-3 ECT implant. Stage 1 (Phase I) patients will undergo explantation at year 2. Those ...
Eligibility Criteria
Inclusion
- Key
- Diagnosis of Active (recurrent or persistent) subfoveal CNV lesions secondary to AMD in the study eye
- Prior Intravitreal Anti-VEGF injections
- Key
Exclusion
- Significant subretinal hemorrhage
- Significant Scar and/or, fibrosis
- Suspected polypoidal choroidopathy, or pigment epithelial tears or rips
- Inadequate response to anti-VEGF therapy
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2016
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT02228304
Start Date
September 1 2014
End Date
April 1 2016
Last Update
July 18 2022
Active Locations (38)
Enter a location and click search to find clinical trials sorted by distance.
1
Associated Retina Consultants, Ltd.
Phoenix, Arizona, United States, 85020
2
Retina-Vitreous Associates Medical Group
Beverly Hills, California, United States, 90211
3
University of California, Irvine, The Gavin Herbert Eye Institute
Irvine, California, United States, 92697
4
Jacobs Retina Center at UCSD
La Jolla, California, United States, 92093